{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:16:23Z","timestamp":1769854583524,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clgc.2019.09.005","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T01:58:34Z","timestamp":1569549514000},"page":"e55-e61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non\u2013muscle-invasive Bladder Cancer: A Propensity Score-matched Analysis"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-912X","authenticated-orcid":false,"given":"Wataru","family":"Fukuokaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Bo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daigo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhiko","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.09.005_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2019.09.005_bib2","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/cncr.22224","article-title":"Long-term outcome of hematuria home screening for bladder cancer in men","volume":"107","author":"Messing","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.09.005_bib3","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clgc.2019.09.005_bib4","first-page":"1233","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.09.005_bib5","first-page":"1120","article-title":"Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup","volume":"161","author":"Solsona","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.09.005_bib6","first-page":"749","article-title":"A\u00a0prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinom","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.09.005_bib7","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2019.09.005_bib8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ctrv.2008.05.004","article-title":"The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer","volume":"34","author":"Petrioli","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2019.09.005_bib9","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr Med Chem"},{"issue":"Suppl","key":"10.1016\/j.clgc.2019.09.005_bib10","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/BF00686935","article-title":"Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin","volume":"30","author":"Akaza","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl","key":"10.1016\/j.clgc.2019.09.005_bib11","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1007\/BF00686918","article-title":"Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborative Group","volume":"35","author":"Shinohara","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2019.09.005_bib12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00345-016-1927-y","article-title":"Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer","volume":"35","author":"Rolevich","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2019.09.005_bib13","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.clgc.2019.09.005_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.clgc.2019.09.005_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","article-title":"Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.09.005_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.clgc.2019.09.005_bib17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1590\/S1677-55382005000300003","article-title":"17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer","volume":"31","author":"Cheng","year":"2005","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.clgc.2019.09.005_bib18","first-page":"378","article-title":"Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone","volume":"158","author":"Kurth","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.09.005_bib19","first-page":"1021","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.09.005_bib20","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00345-018-2299-2","article-title":"Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought","volume":"36","author":"Palou","year":"2018","journal-title":"World J Urol"},{"issue":"Suppl","key":"10.1016\/j.clgc.2019.09.005_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bju.13265","article-title":"Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series","volume":"117","author":"Gendy","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.09.005_bib22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:24Z","timestamp":1761564684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319302745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1558767319302745"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.09.005","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non\u2013muscle-invasive Bladder Cancer: A Propensity Score-matched Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}